Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
depression
Biotech
Gilgamesh links psychedelic to 94% remission rate in depression
The phase 2a data further the biotech’s attempt to follow the trail blazed by Johnson & Johnson.
Nick Paul Taylor
May 27, 2025 11:00am
Neumora rethinks depression drug strategy after ph. 3 failure
Mar 3, 2025 11:00am
Supernus depression drug candidate fails midstage trial
Feb 19, 2025 6:40am
Irish biotech's inhaled drug reduces depression in phase 2 trial
Feb 3, 2025 8:15am
Takeda regains home rights to depression drug from Neurocrine
Jan 28, 2025 4:16am
Neumora's dig into phase 3 depression data disappoints analysts
Jan 15, 2025 9:35am
